ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Clinical Impact of 18F-FDG-PET/CT in Living Donor Liver Transplantation for Advanced Hepatocellular Carcinoma

S. Lee, S. Kim.

Liver Cancer Center, National Cancer Center, Goyang, Korea.

Meeting: 2015 American Transplant Congress

Abstract number: D186

Keywords: Hepatocellular carcinoma

Session Information

Session Name: Poster Session D: Liver Transplantation for Hepatocellular Carcinoma

Session Type: Poster Session

Date: Tuesday, May 5, 2015

Session Time: 5:30pm-6:30pm

 Presentation Time: 5:30pm-6:30pm

Location: Exhibit Hall E

Background: The relevant number of patients with hepatocellular carcinoma (HCC) beyond the Milan criteria has undergone living donor liver transplantation (LDLT). However, the prognostic factors for these patients with advanced HCC are not well established.

Methods: From March 2005 to May 2013, 280 patients with HCC underwent LDLT in the National Cancer Center. Among these, patients beyond the Milan criteria were retrospectively enrolled. We analyzed the prognostic significance of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG-PET/CT) for selecting appropriate candidates.

Results: Among total 280 patients, 147 patients (52.5%) were confirmed to have HCC beyond the Milan criteria using pathological reports. The patients who met and exceeded the Milan criteria had 5-year overall survival (OS) rates of 87.2% and 64.6%, respectively, (p < 0.001). In multivariable analysis for OS and DFS in patients beyond the Milan criteria, PET/CT positivity [hazard ratio (HR) 2.714, p = 0.013 for OS; HR 3.803, p < 0.001 for DFS], total tumor size over 10 cm (HR 2.333, p = 0.035 for OS; HR 3.334, p = 0.001 for DFS), and microvascular invasion (HR 2.917, p = 0.025 for DFS) were significant prognostic factors. In particular, patients beyond the Milan criteria with a PET/CT-negative status and total tumor size < 10 cm showed similar OS and DFS in comparison with those within the Milan criteria.

Conclusions: A PET/CT status in LDLT is a useful marker to predict survival of patients with advanced HCC.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Lee S, Kim S. Clinical Impact of 18F-FDG-PET/CT in Living Donor Liver Transplantation for Advanced Hepatocellular Carcinoma [abstract]. Am J Transplant. 2015; 15 (suppl 3). https://atcmeetingabstracts.com/abstract/clinical-impact-of-18f-fdg-petct-in-living-donor-liver-transplantation-for-advanced-hepatocellular-carcinoma/. Accessed May 9, 2025.

« Back to 2015 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences